 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /vɔːrtiˈɒksətiːn/ vor-tee-OK-sə-teen |
| Trade names | Trintellix, Brintellix, others |
| Other names | Lu AA21004 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614003 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth (film-coated tablets) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 75% (peak at 7–11 hours) |
| Protein binding | 98% |
| Metabolism | Extensive Liver, primarily CYP2D6-mediated oxidation |
| Elimination half-life | 66 hours |
| Excretion | 59% in urine, 26% in feces |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C18H22N2S |
| Molar mass | 298.45 g/mol (379.36 as hydrobromide) g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Vortioxetine, sold under the trade names Trintellix and Brintellix among others, is a medication used to treat major depressive disorder.[3] Effectiveness is viewed as similar to that of other antidepressants.[3] In Britain, it is only recommended in people who have not improved sufficiently on two other antidepressants.[4] It is taken by mouth.[3]
Common side effects include constipation and nausea.[3] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and SIADH.[3] A withdrawal syndrome may occur if the dose is rapidly decreased.[3] Use during pregnancy and breastfeeding is not generally recommended.[4] It is classified as a serotonin modulator.[3] How it works is not entirely clear but is believed to be related to increasing serotonin levels.[3]
It was approved for medical use in the United States in 2013.[3] A month supply in the United Kingdom costs the NHS about £27.72 as of 2019.[4] In the United States the wholesale cost of this amount is about 368.40 USD.[5] In 2017, it was the 312th most commonly prescribed medication in the United States, with more than one million prescriptions.[6]
References edit
- ^ "TGA eBS - Product and Consumer Medicine Information Licence". www.ebs.tga.gov.au. Archived from the original on 29 April 2018. Retrieved 29 April 2018.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 21 January 2021. Retrieved 7 September 2020.
- ^ a b c d e f g h i "Vortioxetine Hydrobromide Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 8 February 2018. Retrieved 18 March 2019.
- ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 376. ISBN 9780857113382.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ "Vortioxetine Hydrobromide - Drug Usage Statistics". ClinCalc. Archived from the original on 21 June 2020. Retrieved 11 April 2020.